Peter Anderson, Maurizio Ghisoli, Brian D Crompton, Kelly S Klega, Leonard H Wexler, Emily K Slotkin, Laura Stanbery, Luisa Manning, Gladice Wallraven, Meghan Manley, Staci Horvath, Ernest Bognar, John Nemunaitis
PURPOSE: Treatment options for recurrent or refractory Ewing's sarcoma (ES) are limited. Vigil is a novel autologous tumor cell therapy expressing bi-shRNA furin/GMCSF plasmid, which previously demonstrated monotherapy activity in advanced ES. Herein we report safety and evidence of benefit to Vigil for ES as potential treatment. PATIENTS AND METHODS: In this pilot trial, eligible patients with recurrent or refractory ES who failed initial standard-of-care therapy received treatment with temozolomide (TEM) 100 mg/m2/day oral and irinotecan (IRI) 50 mg/m2/day oral, Days 1 to 5, in combination with Vigil (1 × 106-107 cells/mL/day intradermal, Day 15), every 21 days (Vigil/TEM/IRI)...
May 1, 2023: Clinical Cancer Research